Drug Creation Partnerships
Leverage Absci's AI and wet lab platform for rapid discovery of breakthrough biologics.
Executive Summary
Absci offers drug creation partnerships, enabling pharmaceutical and biotech companies to utilize its Integrated Drug Creation™ platform. This platform combines generative AI with high-throughput wet lab capabilities to accelerate the discovery and development of novel biologics. The collaboration aims to bring breakthrough therapeutics to patients faster by optimizing lead candidates and designing de novo antibodies. Partnerships focus on leveraging Absci's expertise for novel biologic discovery, including target identification and lead optimization across various therapeutic indications. Absci is actively progressing existing partnerships and is poised to establish new collaborations to expand its impact in the biopharmaceutical industry.
Use Cases
- Accelerating novel biologic discovery
- AI-driven lead optimization for therapeutic candidates
- De novo antibody design and engineering
- Discovery of new drug targets through reverse immunology
Features
Intelligence
- Generative AI for Biologic Design: Leverages advanced generative AI to design novel antibodies and other biologics with desired properties.
- AI Lead Optimization: Applies AI to optimize existing lead candidates for improved efficacy, safety, and manufacturability.
- High-Throughput Wet Lab Screening: Integrates robotic wet lab capabilities for rapid experimental validation and data generation to inform AI models.
- Reverse Immunology for Target Discovery: Pioneers a natural immunology-grounded approach to discover novel drug targets.
Technical Specifications
- Architecture
- Integrated platform combining generative AI models with high-throughput robotic wet lab systems.
- Deployment
- Service-based partnership
AI/ML Stack
- Generative AI
- Machine Learning
Pricing
- Model
- Partnership-based, milestone-driven
- Starting Price
- Contact sales
- Target Customer
- Mid-Market,Enterprise
- Contract Type
- Project-based, multi-year
- Free Trial
- No
About Absci
Absci is a clinical-stage biopharmaceutical company that leverages its Integrated Drug Creation™ platform, combining generative AI with synthetic biology to design and advance novel biologic therapeutics faster. They aim to create better biologics for patients by unifying drug discovery and cell line development into one simultaneous process.